Data Sheet (Cat.No.T18066)

TargetMol

Lenalidomide-OH

Chemical Properties



CAS No. : 1416990-08-3

Formula: C13H12N2O4

Molecular Weight: 260.25

Storage: Keep away from direct sunlight
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	Lenalidomide-OH is an analog of Lenalidomide, a cereblon ligand for E3 ubiquitin ligase (CRBN), used for CRBN protein recruitment. It is able to attach to protein ligands using linkers to form PROTAC.
Targets(IC50)	Ligands for E3 Ligase,PROTAC Linker
In vitro	Lenalidomide-OH can be linked to a protein ligand via a linker to form PROTACs, which induce the ubiquitination-mediated degradation of cancer-promoting proteins [1].

Solubility Information

Solubility	DMSO: 11 mg/mL (42.27 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (7.68 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	3.8425 mL	19.2123 mL	38.4246 mL
5 mM	0.7685 mL	3.8425 mL	7.6849 mL
10 mM	0.3842 mL	1.9212 mL	3.8425 mL
50 mM	0.0768 mL	0.3842 mL	0.7685 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Jaime-Figueroa S, et al. Design, synthesis and biological evaluation of Proteolysis Targeting Chimeras (PROTACs) as a BTK degraders with improved pharmacokinetic properties. 2020 Feb 1;30(3):126877.